17159-82-9

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
1,4-dioxaspiro[4.5]decan-8-ylmethanol is utilized as a synthetic building block for the development of pharmaceuticals and agrochemicals. Its unique structure and reactivity make it a valuable component in the synthesis of various bioactive compounds, contributing to the advancement of new drugs and agricultural products.
Used in Fragrance and Flavor Industries:
1,4-dioxaspiro[4.5]decan-8-ylmethanol is employed as a key ingredient in the production of fragrances and flavors. Its ability to dissolve in water and organic solvents allows for its incorporation into a wide range of products, enhancing their sensory properties and appeal.
Used in Material Science:
1,4-dioxaspiro[4.5]decan-8-ylmethanol is used in the creation of novel materials, leveraging its chemical properties to develop innovative substances with unique characteristics. Its versatility in this field contributes to the advancement of material science and the development of new applications.
Used in Bioactive Compound Research:
Due to its reactivity and structural features, 1,4-dioxaspiro[4.5]decan-8-ylmethanol is also used in the research and development of bioactive compounds. Its potential to interact with biological systems makes it a promising candidate for the discovery of new therapeutic agents and other bioactive substances.

Upstream product

• 26845-47-6 methyl 1,4-dioxaspiro[4.5]decane-8-carboxylate 
• 51656-90-7 8-methylene-1,4-dioxaspiro[4.5]decane 
• 72445-21-7 1,4-dioxaspiro-<4,5>dec-7-ene-8-methanol 
• 38580-68-6 4-hydroxymethyl-cyclohexanone 
• 107-21-1 ethylene glycol 
• 3618-03-9 methyl 4-hydroxycyclohexanecarboxylate 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 6297-22-9 4-carbomethoxycyclohexanone 
• 3289-28-9 ethyl cyclohexanecarboxylate 
• 93245-98-8 1,4-dioxaspiro[4.5]decane-8-carbaldehyde 
• 1489-97-0 ethyl 1,4-dioxaspiro[4.5]decane-8-carboxylate 
• 3685-22-1 4-hydroxycyclohexanecarboxylic acid 
• 183-97-1 1,4,9,12-Tetraoxa-dispiro[4.2.4.2]tetradecane 

Downstream Products

• 74286-87-6 8-(bromomethyl)-1,4-dioxaspiro<4,5>decane 
• 93245-98-8 1,4-dioxaspiro[4.5]decane-8-carbaldehyde 
• 599174-24-0 8-(4-methoxy-benzyloxymethyl)-1,4-dioxa-spiro[4.5]decane 
• 38580-68-6 4-hydroxymethyl-cyclohexanone 
• 599174-28-4 C₃₂H₄₂N₄O₇S 
• 58230-40-3 9-benzoyl-3-hydroxymethyl-1,2,3,4-tetrahydrocarbazole 
• 1095989-98-2 (5R)-3-[4-(1,4-dioxaspiro[4.5]dec-8-ylmethoxy)benzyl]-5-methyl-1,3-oxazolidin-2-one 
• 1184953-75-0 1-benzenesulfonyl-4-(1,4-dioxaspiro[4.5]dec-8-ylmethoxymethyl)-1H-indole 
• 1184953-72-7 1-benzenesulfonyl-5-(1,4-dioxaspiro[4.5]dec-8-ylmethoxymethyl)-1H-indole 
• 1358762-61-4 8-benzyloxymethyl-1,3-diaza-spiro[4.5]decane-2,4-dione 
• 1358762-63-6 8-(p-toluenesulfonyloxymethyl)-1,3-diaza-spiro[4.5]decane-2,4-dione 
• 1187964-14-2 ethyl 3-{1,4-dioxaspiro[4.5]decan-8-yl}propanoate 
• 58012-66-1 3-(4-oxocyclohexyl)propionic acid ethyl ester 

Relevant academic research and scientific papers

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

3-(dimethylaminomethyl) cyclohex-4-alcohol derivative as well as preparation method and pharmaceutical application thereof

The invention belongs to the field of pharmacy, and relates to a 3-(dimethylaminomethyl) cyclohex-4-alcohol derivative with a general formula (I) or a salt thereof and a preparation method, and relates to an application of the compound in treatment of opioid receptor mediated diseases. The present invention provides a pharmaceutically acceptable solvate or hydrate of a compound of formula (I), and also provides a pharmaceutical composition comprising: a compound of formula (I) or a pharmaceutically acceptable salt, solvate or hydrate thereof; and a pharmaceutically acceptable carrier. The medicine prepared from the compound can be used for treating or improving diseases related to an opioid receptor; wherein the diseases can be selected from but not limited to pain, gastrointestinal diseases and depression.

LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT

PROBLEM TO BE SOLVED: To improve Δn of a liquid crystal compound. SOLUTION: One aspect of the present invention is a liquid crystal compound represented by general formula (i) [where Ri1 is a C1 to 15 alkyl group or the like, Ri2 is

Design, synthesis and SAR study of bridged tricyclic pyrimidinone carboxamides as HIV-1 integrase inhibitors

The design, synthesis and structure-activity relationships associated with a series of bridged tricyclic pyrimidinone carboxamides as potent inhibitors of HIV-1 integrase strand transfer are described. Structural modifications to these molecules were made in order to examine the effect on potency towards wild-type and clinically-relevant resistant viruses. The [3.2.2]-bridged tricyclic system was identified as an advantageous chemotype, with representatives exhibiting excellent antiviral activity against both wild-type viruses and the G140S/Q148H resistant virus that arises in response to therapy with raltegravir and elvitegravir.

1-METHYL-4-[(4-PHENYLPHENYL)SULFONYLMETHYL]CYCLOHEXYANOL AND 1-METHYL-4-[[4-(2-PYRIDYL)PHENYL]SULFONYLMETHYL]CYCLOHEXANOL COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted 1-methyl-4-[(4-phenylphenyl)sulfonylmethyl]cyclohexanol and 1-methyl-4-[[4-(2-pyridyl)phenyl]sulfonylme

DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES

Provided herein are dihydropyrimidine derivatives which are useful in the treatment of HBV infection or HBV-induced diseases, as well as pharmaceutical or medical applications thereof.

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

CRYSTAL FORM OF 4H-PYRAZOLO[1,5-alpha]BENZOIMIDAZOLE COMPOUND, PREPARATION METHOD THEREOF AND INTERMEDIATE THEREOF

The invention discloses a crystal form A of a compound (I) and a preparation method thereof, and further discloses an application of the crystal form A as a PDE2 or TNF-α inhibitor.

PYRIDINE-1-OXIDE DERIVATIVES AND THEIR USE AS FACTOR XIA INHIBITORS

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

Photochemical Homologation for the Preparation of Aliphatic Aldehydes in Flow

Cheap and readily available aqueous formaldehyde was used as a formylating reagent in a homologation reaction with nonstabilized diazo compounds, enabled by UV photolysis of bench-stable oxadiazolines in a flow photoreactor. Various aliphatic aldehydes were synthesized along with the corresponding derivatized alcohols and benzimidazoles. No transition-metal catalyst or additive was required to affect the reaction, which proceeded at room temperature in 80 min.